Selected article for: "ATP bind and helicase activity"

Author: Essegian, Derek J.; Cunningham, Tyler A.; Zerio, Christopher J.; Chapman, Eli; Schatz, Jonathan; Schürer, Stephan C.
Title: Molecular Dynamics Simulations Identify Tractable Lead-like Phenyl-Piperazine Scaffolds as eIF4A1 ATP-competitive Inhibitors
  • Cord-id: es57lp1t
  • Document date: 2021_9_15
  • ID: es57lp1t
    Snippet: [Image: see text] eIF4A1 is an ATP-dependent RNA helicase whose overexpression and activity have been tightly linked to oncogenesis in a number of malignancies. An understanding of the complex kinetics and conformational changes of this translational enzyme is necessary to map out all targetable binding sites and develop novel, chemically tractable inhibitors. We herein present a comprehensive quantitative analysis of eIF4A1 conformational changes using protein–ligand docking, homology modelin
    Document: [Image: see text] eIF4A1 is an ATP-dependent RNA helicase whose overexpression and activity have been tightly linked to oncogenesis in a number of malignancies. An understanding of the complex kinetics and conformational changes of this translational enzyme is necessary to map out all targetable binding sites and develop novel, chemically tractable inhibitors. We herein present a comprehensive quantitative analysis of eIF4A1 conformational changes using protein–ligand docking, homology modeling, and extended molecular dynamics simulations. Through this, we report the discovery of a novel, biochemically active phenyl-piperazine pharmacophore, which is predicted to target the ATP-binding site and may serve as the starting point for medicinal chemistry optimization efforts. This is the first such report of an ATP-competitive inhibitor for eiF4A1, which is predicted to bind in the nucleotide cleft. Our novel interdisciplinary pipeline serves as a framework for future drug discovery efforts for targeting eiF4A1 and other proteins with complex kinetics.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active site: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and active site binding: 1, 2, 3, 4
    • absence presence and active structure: 1
    • absence presence and activity show: 1, 2, 3
    • acceptor hydrogen bond donor and active site: 1, 2, 3
    • acceptor hydrogen bond donor and active site binding: 1
    • active site and adenine base: 1, 2
    • active site binding and adenine base: 1